Semper Paratus Acquisition (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the stock.
Semper Paratus Acquisition Price Performance
TVGN stock remained flat at $1.20 during mid-day trading on Wednesday. 597,872 shares of the company's stock were exchanged, compared to its average volume of 5,075,350. The business has a 50 day moving average of $1.15 and a 200 day moving average of $1.20. Semper Paratus Acquisition has a twelve month low of $0.26 and a twelve month high of $3.09.
Insiders Place Their Bets
In other Semper Paratus Acquisition news, CEO Ryan H. Saadi sold 1,438,206 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $1.23, for a total value of $1,768,993.38. Following the transaction, the chief executive officer now directly owns 116,814,453 shares in the company, valued at $143,681,777.19. This represents a 1.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 73.24% of the company's stock.
Hedge Funds Weigh In On Semper Paratus Acquisition
Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in shares of Semper Paratus Acquisition by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after purchasing an additional 16,695 shares in the last quarter. Barclays PLC boosted its stake in shares of Semper Paratus Acquisition by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after purchasing an additional 12,847 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Semper Paratus Acquisition during the fourth quarter valued at approximately $55,000. Nuveen LLC bought a new position in shares of Semper Paratus Acquisition during the first quarter valued at approximately $97,000. Finally, Northern Trust Corp boosted its stake in shares of Semper Paratus Acquisition by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after purchasing an additional 13,595 shares in the last quarter.
About Semper Paratus Acquisition
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
See Also
Before you consider Semper Paratus Acquisition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Semper Paratus Acquisition wasn't on the list.
While Semper Paratus Acquisition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
